Liver Ultrasound for Fatty Liver: How to Read Results, Stages & What Happens Next

By Guillermo Salinas Araya · June 1, 2026 · Educational Material

In 1980, pathologist Jurgen Ludwig described in Mayo Clinic Proceedings an entity without a name: livers infiltrated with fat in patients who had never touched alcohol. Forty-six years later, that finding affects one in three adults in the Western world.

Medical Definition of Liver Ultrasound Findings

The term liver ultrasound findings refers to a clinical condition with diagnostic criteria established in recent medical literature. Understanding it requires distinguishing between the entity itself, its forms of presentation, and its underlying mechanisms. Updated international guidelines have reformulated several of these criteria over the past decade, expanding what conventional clinical practice has not yet incorporated.¹

Pathophysiology: How It Develops

The pathophysiological cascade of fatty liver disease involves multiple parallel mechanisms that feed back on each other. The monocausal hypothesis has been replaced by integrative models that recognize the interaction of several axes:²

• Endocrine-metabolic axis: impaired insulin sensitivity and hepatic lipogenesis.
• Inflammatory axis: low-grade pro-inflammatory cytokines (TNF-α, IL-6, elevated high-sensitivity CRP).
• Mitochondrial axis: respiratory chain dysfunction and increased reactive oxygen species.
• Intestinal axis: microbiome alterations, increased intestinal permeability, endotoxin translocation.
• Neuroendocrine axis: dysregulation of the hypothalamic-pituitary-adrenal axis with chronically elevated cortisol.

The accumulation of these five simultaneous impacts is what distinguishes the pathological state from the physiological state of compensatory tolerance. Patients can spend years with one or two active axes without clinical manifestation — until the convergence overwhelms adaptive mechanisms.

Clinical Signs and Symptoms

Clinical presentation is heterogeneous. In early stages, most patients are oligosymptomatic or asymptomatic.³ Signs and symptoms that suggest the diagnosis include:

• Unexplained fatigue, especially after meals
• Progressive increase in waist circumference
• Skin changes (spots, skin tags, hair alterations)
• Sleep-wake cycle disruptions
• Neurocognitive symptoms: brain fog, difficulty concentrating, irritability
• Nonspecific laboratory findings: mildly elevated CRP, mild liver function or lipid abnormalities frequently labeled as "high normal"
• Subtle ultrasound findings requiring targeted examination

Long-Term Consequences if Left Unaddressed

The natural history of fatty liver disease without adequate intervention involves silent but predictable progression:⁴

• Increased cardiovascular risk independent of cholesterol levels
• Accelerated development of type 2 diabetes in patients with prediabetes
• Progression toward structural organ damage within 5 to 15 years
• Increased cancer risk documented in longitudinal cohorts
• Progressive functional decline reducing quality of life and healthy life expectancy

The therapeutic opportunity window — the period during which the condition is completely reversible — is proportional to exposure time and the number of compromised pathophysiological axes. Every year lost without comprehensive intervention narrows that window.

Can It Be Reversed?

Contemporary clinical evidence is compelling: in pre-irreversible stages, reversal is possible. But it requires addressing all five pathophysiological axes simultaneously, not sequentially or in isolation. This is where conventional approaches fail: they intervene on a single axis and leave the other four active.

The educational protocol we designed — The Salinas Method — comprises 8 sequential phases. Each phase addresses a distinct mechanism in the cascade. Phases 1 and 2 prepare the cellular terrain and correct the microbiome. Phases 3 through 6 dismantle low-grade inflammation, mitochondrial dysfunction, insulin resistance, and cortisol axis disruption. Phases 7 and 8 consolidate the change and prevent relapse.

It's not a diet. It's not isolated fasting. It's not a supplement. It's a guided educational protocol, step by step, based on the most recent clinical evidence and designed so patients understand the why behind each action.

References

1. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980. PubMed
2. Eslam M, et al. A new definition for metabolic dysfunction-associated fatty liver disease. J Hepatol. 2020. PubMed
3. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2016. PubMed
4. Tilg H, Moschen AR. Evolution of inflammation in NAFLD: multiple parallel hits hypothesis. Hepatology. 2010. PubMed
5. Chalasani N, et al. The diagnosis and management of NAFLD: practice guidance from AASLD. Hepatology. 2018. PubMed
6. Wong RJ, et al. NASH is the second leading etiology of liver disease. Gastroenterology. 2015. PubMed